Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

From STAT’s Andrew Joseph: GSK said this morning that it would buy RAPT Therapeutics in a deal worth $2.2 billion, picking up ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.